Other
ALK Inhibitor
ALK Inhibitor is an intervention with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
OTHER
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Other(2)
Detailed Status
unknown2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 21 (50.0%)
N/A1 (50.0%)
Trials by Status
recruiting133%
unknown267%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_2
A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors
NCT06322095
unknown
The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring
NCT04499794
unknownnot_applicable
ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.
NCT03792568
Clinical Trials (3)
Showing 3 of 3 trials
NCT06322095Phase 2
A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors
NCT04499794
The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring
NCT03792568Not Applicable
ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.
All 3 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 3